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Background: Many studies have investigated whether pleural cholesterol levels can aid in diagnosis of pleural exudates,
and the results have varied considerably. To gain a more reliable answer to this question, we meta-analyzed the literature
on using pleural cholesterol or the ratio of cholesterol in pleural fluid to cholesterol in serum (P/S cholesterol ratio) as
diagnostic tests to help identify pleural exudates.
Methods: Literature databases were systematically searched for studies examining accuracy of pleural cholesterol or P/S
cholesterol ratios for diagnosing pleural exudates. Data on sensitivity, specificity, positive/negative likelihood ratio
(PLR/NLR), and diagnostic odds ratio (DOR) were pooled using bivariate-effects models. Summary receiver operating
characteristic (SROC) curves and area under the curve (AUC) were used to summarize overall test performance.
Results: Our meta-analysis included up to 20 studies involving 3,496 subjects. Summary estimates for pleural cholesterol
in the diagnosis of pleural exudates were as follows: sensitivity, 0.88 (95%CI 0.84 to 0.92); specificity, 0.96 (95% CI 0.92 to
0.98); PLR, 20.31 (95% CI 11.21 to 36.78); NLR, 0.12 (95% CI 0.09 to 0.17); DOR, 167.06 (95% CI 76.79 to 363.95); and AUC
0.97 (95% CI 0.95 to 0.98). The corresponding summary performance estimates for using the P/S cholesterol ratio were as
follows: sensitivity, 0.94 (95% CI 0.92 to 0.96); specificity, 0.87 (95% CI 0.83 to 0.91); PLR 7.46 (95% CI, 5.47 to 10.19); NLR,
0.07 (95% CI 0.05 to 0.10); DOR, 107.74 (95% CI 60.91 to 190.60); and AUC 0.97 (95% CI 0.95 to 0.98).
Conclusions: Both pleural cholesterol level and the P/S cholesterol ratio are helpful for the diagnosis of pleural exudates.
Nevertheless, the results of pleural cholesterol assays should be interpreted in parallel with the results of traditional tests
and clinical information.
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Pleural effusion often develops in patients with thoracic
or systemic diseases [1]. Such effusion has traditionally
been classified as transudate or exudate based on the eti-
ology and underlying pathology, and differentiating the
two types of pleural effusion is critical for guiding treat-
ment [2,3]. Transudates are usually taken as a sign of
underlying congestive heart failure, cirrhosis, or nephrosis,
which then becomes the focus of treatment. Because in
the case of a transudate, aetiology and therapy are directed* Correspondence: wenfuqiang.scu@gmail.com
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unless otherwise stated.to the underlying congestive heart failure, cirrhosis, or
nephrosis. Alternatively, exudates are usually taken as a
sign of, inflammatory disorders or malignancy, leading to
more extensive diagnostic procedures [4,5].
The criteria most widely used to differentiate exudates
and transudates in patients with pleural effusions are
Light's criteria, established by Light et al. in 1972 [6].
These criteria rely on levels of total protein and of lac-
tate dehydrogenase [6]. The criteria maximize sensitivity
at the expense of specificity: they typically identify 98%
of pleural exudates, but they misclassify approximately
25% of transudates as exudates [7]. As a result, patients
misclassified with exudate undergo unnecessary and risky
invasive diagnostic procedures, such as thoracoscopic
pleural biopsy and image-guided percutaneous pleurald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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methods to differentiate exudative and transudative pleural
effusions [9].
Since Light's criteria were published in 1972, pleural
cholesterol levels have been explored for their usefulness
in diagnosing pleural exudates. Cellular degeneration
and vascular leakage due to increased permeability are
thought to elevate pleural cholesterol levels [10]. Several
studies suggest that pleural cholesterol is increased in
pleural exudates, making it a potential biomarker for
differentiating exudative and transudative pleural effu-
sions [11]. Studies have come to conflicting conclusions
about whether pleural cholesterol levels can provide ad-
equate differentiating power, and other studies have ex-
plored the diagnostic potential of the ratio of cholesterol
in pleural fluid to cholesterol in serum (P/S cholesterol
ratio) and come to similarly conflicting conclusions [11].
To help gain more reliable insights, we meta-analyzed
the literature on using pleural cholesterol level or the
P/S cholesterol ratio to distinguish pleural exudates from
transudates.
Methods
The present meta-analysis was performed using the guide-
lines of the Preferred Reporting Items for Systematic Re-
views, as well as the Meta-analysis Statement and methods
recommended by the Cochrane Diagnostic Test Accuracy
Working Group [12]. Institutional review board approval
was not required for this retrospective meta-analysis.
Two investigators (YCS and HZ) searched in PUBMED
and EMBASE for relevant articles published up to October
2013 in which the following search terms were used as
Medical Headings and/or text words: “cholesterol”, “pleural
effusion”, and “pleural fluid”. The syntax for the PUBMED
searches was as follows: “pleural effusion” OR “pleural
fluid” AND “cholesterol”. Reference lists of the included
studies and review articles were also checked to identify
additional studies.
Studies were included if they fulfilled the following cri-
teria: (1) they were original research articles published in
English; (2) they examined the ability of pleural cholesterol
level or P/S cholesterol ratio for differentiating pleural
transudates and exudates in humans; and (3) they re-
ported sufficient data to allow calculation of true positive
(TP), false positive (FP), false negative (FN), and true
negative (TN) rates. Conference proceedings and studies
published only as abstracts were excluded. To avoid se-
lection bias, we also excluded studies involving fewer
than 20 patients.
Two reviewers (LC and TW) independently identified
eligible studies and extracted data, with which they pre-
pared 2 × 2 tables of diagnostic performance. In case of
disagreement, the two reviewers arrived at a consensus.
The quality of the selected studies was assessed usingthe 14-items Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) list [13].
Using bivariate regression, we calculated pooled esti-
mates of sensitivity (SEN) and specificity (SPE) as the
main outcome measures, and we constructed summary
receiver operating characteristic (SROC) curves [14]. The
bivariate approach investigates potential between-study
heterogeneity and takes into account possible correlation
between SEN and SPE. Based on the pooled estimates of
SEN and SPE, we calculated positive likelihood ratios
(PLR) and negative likelihood ratios (NLR). SEN and SPE
estimates were paired to generate diagnostic odds ratios
(DOR), which we used as an overall index of diagnostic ac-
curacy. DOR relates the odds of positive test results in
those with the condition with the odds of positive test re-
sults in those without the condition.
Heterogeneity was assessed using the I2 inconsistency
test. I2 > 50% indicated substantial heterogeneity, which
was then analyzed through subgroup analyses. The fol-
lowing covariates were clearly reported by more than 80%
of included studies and so were analyzed as possible
sources of heterogeneity: publication year (before 2000 vs.
after 2000), design (cross sectional vs. non-cross sectional),
data collection (prospective vs. retrospective), sampling
method (consecutive/random vs. nonconsecutive/non-
random/not reported), blinding (yes vs. no or not re-
ported), detection method (enzymatic colorimetric method
vs. other), sample size (<100 subjects vs. ≥ 100 subjects),
QUADAS score (<9 vs. ≥9), and cholesterol cut-off value
(60 mg/dl vs. other) [11].
Deeks’s funnel plot was used to detect publication bias
[15]. Post-test probability (PTP) was calculated using the
overall prevalence of 20% with Fagan nomograms. All
analyses were performed using the “Midas” module in
STATA 12.0 (Stata Corp., College Station, TX). All stat-
istical tests were two-sided, with P values less than 0.05
taken as the threshold for statistical significance.
Results
After systematically searching literature databases and
manually searching references lists in relevant reviews
and studies, we included 20 studies examining the diag-
nostic accuracy of cholesterol levels in patients with
pleural exudates [16-35]. Studies were excluded mainly
because they did not examine diagnostic performance,
they did not report sufficient data to construct 2 × 2 ta-
bles, or they involved fewer than 20 patients. Figure 1
outlines the process of selecting studies.
Quality of reporting and study design
The final set of 20 studies involved 3,496 subjects, com-
prising 2,548 patients with pleural exudates and 948
with transudates. Of the included studies, 19 exam-
ined the ability of pleural cholesterol concentrations to
Figure 1 Flow diagram of study selection.
Table 1 Clinical summary of included studies examining the diagnostic accuracy of pleural cholesterol level
Study (ref no.) Year Country No. patients Standard Method Cut-off
(mg/l)




Hamm H [16] 1987 Germany 31 31 Clinical criteria ECM 60 28 3 3 28 8 9/30
Valdés L [17] 1991 Spain 188 65 Clinical criteria ECM 55 171 0 17 65 9 14/65
Romero S [18] 1993 Spain 253 44 Clinical criteria ECM 60 206 4 47 40 8 10/44
Burgess LJ [19] 1995 South Africa 270 123 Clinical criteria ESM 50 184 11 86 112 7 19/112
Costa M [20] 1995 Chile 131 49 Clinical criteria ECM 45 118 0 13 49 9 9/49
Gil Suay V [21] 1995 Spain 156 48 Clinical criteria ECM 54 149 4 7 44 8 17/48
Garcia-Pachon E [22] 1996 Spain 118 35 Clinical criteria NA 50 107 1 11 34 10 9/35
Kalayci AG [23] 1996 Turkey 40 20 Clinical criteria ECM 40 36 1 4 19 9 NA
Metintaş M [24] 1997 Turkey 72 21 Clinical criteria ECM 60 54 3 18 18 10 4/21
Gázquez I [25] 1998 Spain 155 38 Clinical criteria ECM 50 130 6 25 32 7 11/38
Romero S [26] 2000 Spain 182 61 Clinical criteria ECM 60 155 5 27 56 9 9/61
Yilmaz A [27] 2000 Turkey 150 105 Clinical criteria ECM 60 143 4 7 101 8 13/105
Porcel JM [28] 2001 Spain 139 32 Clinical criteria ECM 60 111 1 28 31 9 8/32
Alexandrakis MG [29] 2002 Greece 82 24 Light's criteria NA 65 76 0 6 24 10 NA
Guleria R [30] 2003 India 50 25 Clinical criteria NA 60 44 0 6 25 9 5/25
Leers MP [31] 2007 Netherlands 300 108 Clinical criteria ECM 60 227 2 73 106 11 29/108
Razi E [32] 2008 Iran 70 49 Light's criteria NA 38 61 10 9 39 8 NA
Hamal AB [33] 2013 Nepal 43 19 Clinical criteria ECM 45 42 0 1 19 12 NA
Patel AK [34] 2013 India 49 11 Clinical criteria NA 60 48 0 1 11 11 0/11
Abbreviations: ECM, enzymatic colorimetric method; ESM, enzymatic spectrophotometric method; Exu, pleural exudate; Trans, transudate; TP, no. of true positives;
FP, no. of false positives; FN, no. of false negatives; NA, not applicable; TN, no. of true negatives; QUADAS, quality assessment of diagnostic accuracy studies.
*No. of transudates misclassified as exudates based on Light’s criteria (misclassifications/total).
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Table 2 Clinical summary of included studies examining the diagnostic accuracy of the ratio of cholesterol in pleural
fluid to cholesterol in serum
Study (ref. no.) Year Sample size Cut-off TP FP FN TN
Exudates Transudates
Hamm H [16] 1987 31 31 0.3 29 2 2 29
Valdés L [17] 1991 188 65 0.3 174 8 14 57
Romero S [18] 1993 249 42 0.3 222 12 27 30
Burgess LJ [19] 1995 270 123 0.3 240 23 30 100
Gil Suay V [21] 1995 156 48 0.32 152 4 4 44
Garcia-Pachon E [22] 1996 118 35 0.3 109 1 9 34
Kalayci AG [23] 1996 40 20 0.3 38 2 2 18
Metintaş M [24] 1997 72 21 0.3 67 6 5 15
Romero S [26] 2000 182 61 0.3 171 11 11 50
Yilmaz A [27] 2000 150 105 0.3 143 11 7 94
Horvath LL [35] 2001 69 40 0.3 68 2 1 38
Alexandrakis MG [29] 2002 82 24 0.38 77 3 5 21
Guleria R [30] 2003 50 25 0.4 49 4 1 21
Abbreviations: TP, no. of true positives; FP, no. of false positives; FN, no. of false negatives; NA, not applicable; TN, no. of true negatives.
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ined the ability of the P/S cholesterol ratio to do this. In-
cluded studies were published between 1987 and 2013. In
all included studies, most studies took into account the
limitations of Light's criteria and therefore diagnosed ex-
udative pleural effusion by combining Light's criteria withFigure 2 Scatterplot of the positive likelihood ratio (PLR) and negativ
concentrations to diagnose exudates.clinical information, treatment response, and other data,
which is widely considered an acceptable basis for exudate
diagnosis. Of the 20 studies, 12 had QUADAS scores ≥9.
Tables 1 and 2 summarize the clinical characteristics of the
patients in each study as well as the QUADAS scores for
each publication.e likelihood ratio (NLR) when using pleural cholesterol
Figure 3 Summary receiver operating characteristic (SROC) curve for pleural cholesterol concentration as a diagnostic test for exudates.
Figure 4 Fagan’s nomogram for likelihood ratios and pre- and
post-test probabilities for using pleural cholesterol levels to
diagnose pleural exudates.
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The following pooled parameters were calculated over
all 19 studies examining pleural cholesterol concentra-
tions for diagnosing exudates: SEN, 0.88 (95% CI: 0.84-
0.91); SPE, 0.96 (95% CI: 0.92-0.98); PLR, 20.31 (95% CI:
11.21-36.78) (Figure 2); NLR, 0.12 (95% CI: 0.09-0.17)
(Figure 2); and DOR, 167.06 (95% CI: 76.69-363.95). All
five performance indices showed high I2 values: SEN,
91.13%; SPE, 74.31%; PLR, 63.7%; NLR, 91.96%; and DOR,
100% (all P < 0.05). This suggests substantial heterogeneity
among the studies.
Figure 3 shows a plot of the rate of true positives as a
function of the rate of false positives for individual studies,
as well as the corresponding SROC curve. Using the bi-
variate approach, which estimates not only the strength
but also the shape of the correlation between SEN and
SPE, we plotted the observed and predicted ellipses
at a 95% confidence level. The AUC was 0.97 (95% CI:
0.95-0.98), indicating a high discriminatory ability of
pleural cholesterol. Fagan’s nomogram for likelihood ratios
(Figure 4) indicated that using cholesterol to detect pleural
exudates increased the post-probability to 83% when the
results were positive and reduced the post-probability to
4% when the results were negative.
Diagnostic accuracy of the P/S cholesterol ratio
A total of 13 studies with 2,297 subjects examined the
ability of the P/S cholesterol ratio to distinguish exu-
dates from transudates. Table 3 summarizes the SEN,
SPE, PLR, NLR, and DOR, while Figure 5 shows the SROC
curve. The AUC was 0.97 (95% CI: 0.95-0.98), suggesting
high overall accuracy.
Table 3 Summary characteristics of diagnostic performance
of pleural cholesterol levels and ratio of cholesterol in
pleural fluid to cholesterol in serum
Parameter Pleural cholesterol
concentrations
Pleural fluid to serum
cholesterol ratio
Sensitivity 0.88 0.94
(95CI: 0.84-0.92) (95CI: 0.92-0.96)
Specificity 0.96 0.87
(95CI: 0.92-0.98) (95CI: 0.83-0.91)
PLR 20.31 7.46
(95CI: 11.21-36.78) (95CI: 5.47-10.19)
NLR 0.12 0.07
(95CI: 0.09-0.17) (95CI: 0.05-0.10)
DOR 167.06 107.74




(95CI: 0.95-0.98) (95CI: 0.95-0.98)
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Significant heterogeneity was identified among included
studies, so we performed subgroup analysis to investi-
gate the possible sources of this heterogeneity. Table 4
summarizes the influence of certain covariates on the
SEN and SPE. SPE was significantly higher with some
covariates, such as QUADAS score or blinding. How-
ever, these covariates did not significantly affect SEN.Figure 5 Summary receiver operating characteristic (SROC) curve for
serum to diagnose pleural exudates.Deeks’ funnel plot asymmetry test was used to assess
likelihood of publication bias in the final set of studies.
The slope coefficient was associated with a P value of
0.50, suggesting symmetry in the data and low likelihood
of such bias (Figure 6).
Discussion
Despite the importance of defining the type of pleural ef-
fusion accurately, current methods lack the power to re-
liably differentiate pleural exudates from transudates [7].
Several studies suggest that pleural cholesterol levels and
the P/S cholesterol ratio may be able to accomplish this,
but the studies have given conflicting results. Our meta-
analysis suggests that both pleural cholesterol level and
P/S cholesterol ratio are useful as tools in the diagnosis
of pleural exudates, though they probably cannot stand
on their own and so should be used in conjunction with
more traditional tests.
Our meta-analysis showed that pleural cholesterol
level was associated with high SEN (0.88, 95% CI: 0.84-
0.91) and SPE (0.96, 95% CI: 0.92-0.98). These findings
suggest that pleural cholesterol may represent a new
milestone in pleural exudate diagnosis. The SROC curve
illustrates overall test performance, and shows the trade-
off between SEN and SPE. Our SROC analysis showed
an AUC of 0.97, suggesting high overall accuracy. An-
other indicator of diagnostic accuracy is DOR, which is
the ratio of the odds of a true positive to the odds of a
false positive; DOR combines SEN and SPE data into a
single number ranging from 0 to infinity, with higher
values indicating better discriminatory test performance.using the ratio of cholesterol in pleural fluid to cholesterol in
Table 4 Subgroup analysis for sensitivity and specificity
Covariate Sensitivity Coefficient Z P Specificity Coefficient Z P
Publication year 0.90 (95% CI 0.84-0.94) 2.19 0.84 0.40 0.97 (95% CI 0.92-0.99) 3.39 0.93 0.35
Method 0.88 (95% CI 0.83-0.92) 2.01 −0.20 0.84 0.96 (95% CI 0.92-0.98) 3.07 −0.10 0.92
Cut-off value 0.86 (95% CI 0.80-0.91) 1.85 −0.96 0.34 0.96 (95% CI 0.91-0.98) 3.08 −0.02 0.99
QUADAS score 0.89 (95% CI 0.84-0.93) 2.07 0.34 0.74 0.98 (95% CI 0.95-0.99) 3.77 3.15 0.00
Sample size 0.87 (95% CI 0.82-0.91) 1.92 −1.03 0.30 0.95 (95% CI 0.91-0.98) 3.02 −0.36 0.72
Prospective 0.90 (95% CI 0.85-0.93) 2.18 1.08 0.28 0.95 (95% CI 0.90-0.98) 2.95 −0.64 0.52
Design 0.90 (95% CI 0.86-0.93) 2.22 1.70 0.09 0.94 (95% CI 0.90-0.97) 2.81 −1.42 0.16
Consecutive 0.87 (95% CI 0.82-0.91) 1.90 −1.50 0.13 0.95 (95% CI 0.91-0.97) 2.87 −1.56 0.12
Blinding 0.88 (95% CI 0.80-0.93) 1.99 −0.16 0.88 0.98 (95% CI 0.95-0.99) 3.95 2.00 0.05
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that assaying pleural cholesterol levels should be helpful
in the diagnosis of pleural exudates.
We further examined the diagnostic accuracy of pleural
cholesterol levels by calculating PLR and NLR, which can
be easier to relate to clinical practice than SROC and
DOR [36]. The pooled PLR value of 20.31 suggests that
patients with pleural exudates have an approximately 20-
fold higher chance of giving a positive pleural cholesterol
test result than do patients without exudates. At the
same time, the pooled NLR was 0.12, indicating that a
negative pleural cholesterol test result is 12% likely to be a
false negative, which is not low enough to rule out pleural
exudates. This comprehensive analysis of the diagnosticFigure 6 Deek’s funnel plot to assess the likelihood of publication biaaccuracy of pleural cholesterol levels suggests that this in-
dicator may not be reliable enough on its own but should
instead be used in conjunction with other conventional
tests. This unreliability may in part reflect the sensitivity
of pleural cholesterol levels to differences in disease condi-
tions, patient population, and environment.
Using the P/S cholesterol ratio instead of absolute
cholesterol levels may help eliminate the effects of such
factors to aid the diagnosis of pleural exudates. Our re-
sults revealed that P/S cholesterol ratio showed even
higher SEN than pleural cholesterol levels (0.94, 95% CI:
0.92-0.96); in addition, the AUC was 0.97, suggesting that
the P/S cholesterol ratio also shows high discriminatory
ability.s.
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to inappropriate patient management or potentially un-
necessary and invasive diagnostic investigations that in-
crease morbidity and health care costs [37]. Therefore
we compared how often clinicians misclassified pleural
transudates as exudates depending on whether they
relied on pleural cholesterol levels or Light’s criteria
(Table 1). Pleural cholesterol levels were associated with
a significantly lower misclassification rate. We conclude
that pleural cholesterol level shows substantial promise
as a supplementary test for distinguishing pleural exu-
dates from transudates.
While meta-analysis is well-suited for generating sum-
mary outcomes, the pooled results can mask heterogen-
eity that should be understood in detail [38]. Indeed we
detected substantial heterogeneity across the included
studies, and subgroup analyses suggest that differences
in QUADAS score accounted for most of the observed
SPE heterogeneity. Such differences did not, however,
significantly affect SEN, suggesting that study quality
had little influence on the TP rate of pleural cholesterol
tests. Given the effect of study quality on SPE and the
low QUADAS scores of several included studies, future
studies should aim for greater rigor in order to decrease
the risk of bias.
Our meta-analysis suggests an association between ele-
vated pleural cholesterol and the presence of pleural ex-
udates, which implies that cholesterol contributes to
exudate pathogenesis. It is not immediately clear how
this happens, so future research should examine this
question in order to provide a biological basis for the
observed association. Our meta-analysis also points out
the need for investigating the effect of cut-off value on
the diagnostic accuracy of pleural cholesterol levels. The
values in our meta-analysis ranged from 38 to 65 mg/dl.
This variation in cut-off value partly reflects differences
in clinical context: a lower cut-off value is typically used
for cardiac patients with pleural effusion than for pa-
tients in cancer institutes. Further work should aim to
identify the cut-off value that provides optimal diagnos-
tic accuracy [11].
The findings of this meta-analysis should be inter-
preted with caution because of several limitations. While
our strict inclusion and exclusion criteria may have
helped reduce selection bias, they led to a relatively
small final set of studies for which statistical power may
be inadequate for drawing definitive conclusions about the
ability of pleural cholesterol levels to discriminate between
exudates and transudates. For example, we included only
studies published in English in a relatively small number
of databases. Our results may be biased by our omission
of unpublished studies, studies published in other lan-
guages and studies published in journals not indexed in
the databases we searched.Conclusions
Our meta-analysis suggests that assaying pleural choles-
terol levels and the P/S cholesterol ratio may signifi-
cantly aid the diagnosis of pleural exudates. In the near
future, cholesterol-based assays may prove useful as a
non-invasive confirmatory test to complement current
screening procedures and as a rapid clinical test to guide
the comprehensive management of patients with pleural
effusion.
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